The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALKERMES PLC | SHS | G01767105 | 307,457 | 4,778,633 | SH | SOLE | 4,626,833 | 0 | 151,800 | ||
NORTHWEST BIOTHERAPEUTICS INC | Common | 66737P600 | 166,043 | 16,721,392 | SH | SOLE | 15,931,392 | 0 | 790,000 | ||
PROTHENA CORP PLC | SHS | G72800108 | 291,135 | 5,527,525 | SH | SOLE | 5,266,864 | 0 | 260,661 | ||
REYNOLDS AMERICAN INC | Common | 761713106 | 539,131 | 7,221,145 | SH | SOLE | 6,873,736 | 0 | 347,409 |